Effects of the HMG-CoA reductase inhibitor-Pravastatin sodium (Mevalotin) on plasma lipid abnormalities in patients with chronic renal failure under hemodialysis.

DOI

Bibliographic Information

Other Title
  • 透析患者の脂質異常に対するＨＭＧ‐ＣｏＡ還元酵素阻害剤　Ｐｒａｖａｓｔａｔｉｎ　ｓｏｄｉｕｍ（Ｍｅｖａｌｏｔｉｎ）の効果
  • Pravastatin sodium (Mevalotin<sup>®</sup>) on plasma lipid abnormalities in patients with chronic renal failure under hemodialysis
  • Pravastatin sodium (Mevalotin<sup>®</sup>) の効果

Search this article

Description

Pravastatin sodium (Mevalotin®), an HMG-CoA reductase inhibitor, was administered to 11 diabetic (DM) and 22 non diabetic (non-DM) patients under regular hemodialysis who showed a high plasma total cholesterol (TC) level (≥220mg/dl) and/or low HDL cholesterol (HDLC) level (≤30mg/dl). They were followed every 4 weeks up to 24 weeks by measuring the plasma lipids level. A significant reduction of IC and LDLC, 19% and 27% each, appeared after 4 weeks' intake of Pravastatin at 10mg/day. These levels had been kept low up to 12 weeks, when they recovered to the starting level by the interruption of the medication, and decreased again by the readministration. HDLC showed a significant but transient increase (12% at 4 and 8 weeks) only in the non-DM group. Triglyceride (TG) decreased significantly (25%) in the non-DM group but not in the DM group. These changes made the atherogenic index (AI: TC-HDLC/HDLC) decline (non-DM: 6.1→4.1, DM: 5.6→4.4).<br>A blood kinetic study of Pravastatin in 5 dialysis patients compaired with the data from 4 normal controls showed a similar level of Cmax (29.7 vs 35.4μg/ml) and a significant prolongation of Tmax (3.9 vs 1.5 hrs) and t1/2 (2.9 vs 1.7 hrs). However, the blood levels of Pravastatin at 12 and 24 hrs after intake were less than 5μg/ml both in the dialysis patients and the controls, suggesting no accumulation effect of this drug in chronic renal failure.<br>In conclusion, Pravastatin was proved to be effective in reducing IC, LDLC and AI in the dialysis patients. The possibility that this improvement of the plasma lipid profile may decrease the atherogenic complications among the dialysis patients has to be examined by long-term clinical observations.

Journal

Keywords

Details 詳細情報について

  • CRID
    1390282679654134528
  • NII Article ID
    130003721016
  • DOI
    10.4009/jsdt1985.24.1385
  • ISSN
    18846211
    09115889
  • Text Lang
    ja
  • Data Source
    • JaLC
    • Crossref
    • CiNii Articles
  • Abstract License Flag
    Disallowed

Report a problem

Back to top